作者
Marc A Rodger, Jean-Christophe Gris, Johanna IP De Vries, Ida Martinelli, Évelyne Rey, Ekkehard Schleussner, Saskia Middeldorp, Risto Kaaja, Nicole J Langlois, Timothy Ramsay, Ranjeeta Mallick, Shannon M Bates, Carolien NH Abheiden, Annalisa Perna, David Petroff, Paulien De Jong, Marion E Van Hoorn, P Dick Bezemer, Alain D Mayhew
发表日期
2016/11/26
期刊
The Lancet
卷号
388
期号
10060
页码范围
2629-2641
出版商
Elsevier
简介
Background
Placenta-mediated pregnancy complications include pre-eclampsia, late pregnancy loss, placental abruption, and birth of a small-for-gestational-age (SGA) neonate. These complications are leading causes of maternal, fetal, and neonatal morbidity and mortality in high-income countries. Affected women are at high risk of recurrence in subsequent pregnancies; however, effective strategies to prevent recurrence are absent. Findings from our previous study-level meta-analysis suggested that low-molecular-weight heparin reduced the risk of recurrent placenta-mediated pregnancy complications. However, we identified significant heterogeneity in the results, possibly due to trial design or inclusion criteria. To identify which patients benefit from, and which outcomes are prevented by, low-molecular-weight heparin, we did an individual patient data meta-analysis.
Methods
We did a systematic review in May …
引用总数
2016201720182019202020212022202320241233140373330219